Prostate cancer risk in men with prostate and breast cancer family history: results from the REDUCE study (R1)

被引:24
|
作者
Thomas, J. -A., II [1 ,2 ]
Gerber, L. [1 ,2 ]
Moreira, D. M. [3 ]
Hamilton, R. J. [4 ]
Banez, L. L. [1 ,2 ]
Castro-Santamaria, R. [5 ]
Andriole, G. L. [6 ]
Isaacs, W. B. [7 ]
Xu, J. [8 ]
Freedland, S. J. [1 ,2 ,9 ]
机构
[1] Duke Univ, Sch Med, Dept Surg, Duke Prostate Ctr,Div Urol Surg, Durham, NC 27710 USA
[2] Durham VA Med Ctr, Surg Sect, Durham, NC USA
[3] Author Smith Inst Urol, New Hyde Pk, NY USA
[4] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[5] GlaxoSmithKline, Res Triangle Pk, NC USA
[6] Washington Univ, Sch Med St Louis, St Louis, MO USA
[7] Johns Hopkins Univ Hosp, Dept Urol, Baltimore, MD 21287 USA
[8] Wake Forest Univ, Ctr Genom & Personalized Med Res, Winston Salem, NC 27109 USA
[9] Duke Univ, Sch Med, Dept Pathol, Durham, NC 27710 USA
关键词
breast cancer; family history; prostate cancer; REDUCE; RELATIVES; METAANALYSIS; MUTATIONS; PROBANDS; ANTIGEN; CANADA; SWEDEN; COHORT;
D O I
10.1111/j.1365-2796.2011.02504.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
. Thomas J-A II, Gerber L, Moreira DM, Hamilton RJ, Banez LL, Castro-Santamaria R, Andriole GL, Isaacs WB, Xu J, Freedland SJ (Durham VA Medical Center, Durham, NC, USA; Duke University School of Medicine, Durham, NC, USA; The Author Smith Institute for Urology, New Hyde Park, NY, USA; Memorial Sloan-Kettering Cancer Center, New York, NY, USA; GlaxoSmithKline, Research Triangle Park, NC, USA; Washington University School of Medicine, St. Louis, MO, USA; Johns Hopkins Hospital, Baltimore, MD, USA; Wake Forest University, Winston-Salem, NC, USA; and Duke University School of Medicine, Durham, NC, USA). Prostate cancer risk in men with prostate and breast cancer family history: results from the REDUCE study (R1). J Intern Med 2012; 272: 8592. Background. To what degree the associations between PCa risk and family history of prostate cancer (PCa) and/or breast cancer (BCa) are attributable to screening biases is unclear. We examined these questions within the REDUCE study, where biopsies were largely independent of prostate specific antigen (PSA) minimizing screening biases. Methods. Data were from REDUCE, which tested dutasteride 0.5 mg daily for PCa risk reduction in men with PSA 2.510.0 ng mL-1 and a negative prestudy biopsy. Among men undergoing at least one on-study biopsy with complete data (n = 6415; 78.1%), the association between family history and PCa risk was tested using multivariate logistic regression adjusting for clinicodemographic characteristics. Results. A family history of PCa alone was associated with increased PCa diagnosis (OR: 1.47, 95%CI: 1.221.77). In North America, PCa family history was not related to PCa diagnosis (OR: 1.02, 95%CI: 0.731.44), whereas outside North America, PCa family history was significantly related to diagnosis (OR: 1.72, 95%CI: 1.382.15) (P-interaction = 0.01). A family history of both PCa and BCa (OR: 2.54, 95%CI: 1.723.75) but not BCa alone (OR: 1.04, 95%CI: 0.841.29) was associated with increased PCa risk versus no family history and irrespective of geographical region. Conclusions. In REDUCE, PCa family history was significantly related to PCa diagnosis, although only for men outside North America. The presence of both PCa and BCa family history significantly increased risk versus PCa family history alone, irrespective of geographical region. Ultimately, our observations may support the need for changes in how we address family history in terms of both risk of PCa diagnosis and general risk stratification.
引用
收藏
页码:85 / 92
页数:8
相关论文
共 50 条
  • [21] Family history and prostate cancer risk
    Lesko, SM
    Rosenberg, L
    Shapiro, S
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 1996, 144 (11) : 1041 - 1047
  • [22] Association between family history of prostate and breast cancer among African-American men with prostate cancer
    Beebe-Dimmer, Jennifer L.
    Drake, Elizabeth A.
    Dunn, Rodney L.
    Bock, Cathryn H.
    Montie, James E.
    Cooney, Kathleen A.
    UROLOGY, 2006, 68 (05) : 1072 - 1076
  • [23] Efficacy and Safety of Dutasteride on Prostate Cancer Risk Reduction in Asian Men: The Results from the REDUCE Study
    Akaza, Hideyuki
    Kanetake, Hiroshi
    Tsukamoto, Taiji
    Miyanaga, Naoto
    Sakai, Hideki
    Masumori, Naoya
    Nakatsu, Hiroomi
    Sagiyama, Kazuyuki
    Sakamoto, Sadaaki
    Endo, Yukihiro
    Yamanouchi, Takayoshi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (03) : 417 - 423
  • [24] Family History of Prostate and Breast Cancer Integrated with a Polygenic Risk Score Identifies Men at Highest Risk of Dying from Prostate Cancer before Age 75 Years
    Plym, Anna
    Zhang, Yiwen
    Stopsack, Konrad H.
    Jee, Yon Ho
    Wiklund, Fredrik
    Kibel, Adam S.
    Kraft, Peter
    Giovannucci, Edward
    Penney, Kathryn L.
    Mucci, Lorelei A.
    CLINICAL CANCER RESEARCH, 2022, 28 (22) : 4926 - 4933
  • [25] Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial
    Chen, Haitao
    Liu, Xu
    Brendler, Charles B.
    Ankerst, Donna P.
    Leach, Robin J.
    Goodman, Phyllis J.
    Lucia, M. Scott
    Tangen, Catherine M.
    Wang, Li
    Hsu, Fang-Chi
    Sun, Jielin
    Kader, A. Karim
    Isaacs, William B.
    Helfand, Brian T.
    Zheng, S. Lilly
    Thompson, Ian M.
    Platz, Elizabeth A.
    Xu, Jianfeng
    PROSTATE, 2016, 76 (12): : 1120 - 1129
  • [26] Examining risk perception among men with a family history of prostate cancer
    Matthew, Andrew G.
    Paradiso, Christina
    Currie, Kristen L.
    Finelli, Antonio
    Hartman, Mary-Ellen
    Trachtenberg, Lianne
    Shuman, Cheryl
    Horsburgh, Sheri
    Chitayat, David
    Trachtenberg, John
    Ritvo, Paul
    PATIENT EDUCATION AND COUNSELING, 2011, 85 (02) : 251 - 257
  • [27] Accuracy of family history of cancer as reported by men with prostate cancer
    King, TM
    Tong, L
    Pack, RJ
    Spencer, C
    Amos, CI
    UROLOGY, 2002, 59 (04) : 546 - 550
  • [28] Risk for death from prostate cancer predicted from complete family history of lethal prostate cancer
    Albright, Frederick S.
    Agarwal, Neeraj
    Lowrance, William T.
    Stephenson, Robert A.
    Cannon-Albright, Lisa A.
    CANCER RESEARCH, 2015, 75
  • [29] Weight Gain and Family History of Prostate or Breast Cancers as Risk Factors for Prostate Cancer: Results of a Case-control Study in Japan
    Mori, Mitsuru
    Masumori, Naoya
    Fukuta, Fumimasa
    Nagata, Yoshie
    Sonoda, Tomoko
    Miyanaga, Naoto
    Akaza, Hideyuki
    Tsukamoto, Taiji
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2011, 12 (03) : 743 - 747
  • [30] Baseline subject characteristics predictive of compliance with study-mandated prostate biopsy in men at risk of prostate cancer: results from REDUCE
    Fischer, S.
    Sun, S.
    Howard, L. E.
    Moreira, D. M.
    Castro-Santamaria, R.
    Andriole, G. L.
    Vidal, A. C.
    Freedland, S. J.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2016, 19 (02) : 202 - 208